1. Scrip
  2. >>Digital Technologies
  3. >>AI

Israel's Medtech Market Evolution: Seeking The Next Big Thing

 
• By Catherine Longworth

Medtronic’s multi-billion-dollar acquisition of Mazor Robotics in 2018 marked a record-breaking milestone for Israel’s life sciences industry as the largest amount ever paid for an Israeli company in the medical sector, beating Mitsubishi Tanabe Pharma’s $1.1 billion acquisition of Neuroderm in 2017. In Vivo investigates how aMoon II, a new VC fund, aims to produce the industry’s next big giant.

Israel’s Medtech Market Evolution feat image
What's next for Israel's medtech sector? • Source: Shutterstock

Following a $1.65 billion mammoth acquisition by Medtronic PLC, Mazor Robotics Ltd. now tops the list as Israel’s most richly valued company in the medical sector. The blockbuster deal, which should help Medtronic carve out a competitive position in spine surgery robotics, was welcomed in Israel as proof of the country’s growing leadership in health care innovation.

Caesarea-based Mazor Robotics first attracted the attention of Medtronic in 2016 when the companies forged an agreement to make Medtronic...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from AI

Amgen Plans AI Investment Amid Strong Sales Growth

 
• By Alaric DeArment

CEO Robert Bradway expressed support on the company’s Q2 earnings call for lower drug prices but said it was “premature” to comment in detail on particular proposals.

Korean Biopharma Catching Up On AI, But What Are The Challenges?

 
• By Jung Won Shin

While South Korea's biopharma sector has made progress in its digital transformation, including the adoption of AI technologies, a recent report has identified multiple remaining challenges.

AI-First, Big Pharma, Chinese Firms In Race - What’s Ahead For PRMT5 Inhibitors

 
• By Vibha Ravi

As AI-driven firms including Insilico, big pharmas J&J, Amgen, GSK and AstraZeneca and Chinese and Indian firms like BeOne and Dr. Reddy’s advance PRMT5 inhibitor candidates, what’s driving interest, what could lead to the first global approval and what are the challenges ahead?

Kris Joshi Named Norstella CEO, Prioritizes AI Innovation

 
• By Aakash Babu

Joshi joins the parent company of Citeline, which houses flagship publications Scrip and Pink Sheet, to focus on AI, business harmonization and long-term growth.

More from Digital Technologies

Beyond AI Hype: Tokyo-1’s Real Answer On How To Innovate Pharma R&D

 
• By Lisa Takagi

Bringing supercomputing power to bear on large-scale calculations for pharma R&D, Tokyo-based Xeureka explains the practical use of AI to empower innovation beyond the hype.

Decentralized Trials Enroll Larger, More Diverse Patient Populations

 
• By Alaric DeArment

A new study by Tufts CSDD performed a deep dive into use of decentralized clinical trial techniques, but one of the study’s authors said DCTs have been dialed back.

Sanofi Links Up Again With Formation To Take Gusacitinib Down New Path

 
• By Kevin Grogan

Deal Snapshot: The Paris-headquartered company has licensed gusacitinib, which was in development for chronic hand eczema, but Sanofi will pursue a new indication for the dual JAK/SYK inhibitor.